Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
Target Hospitality Corp. stock logo
TH
Target Hospitality
$18.55
-2.2%
$17.42
$5.97
$20.85
$1.85B1.491.29 million shs1.63 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+668.51%
Target Hospitality Corp. stock logo
TH
Target Hospitality
0.00%+3.92%+27.93%+6.85%+108.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
Target Hospitality Corp. stock logo
TH
Target Hospitality
$18.55
-2.2%
$17.42
$5.97
$20.85
$1.85B1.491.29 million shs1.63 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+668.51%
Target Hospitality Corp. stock logo
TH
Target Hospitality
0.00%+3.92%+27.93%+6.85%+108.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.27
Hold$55.144.13% Upside
Target Hospitality Corp. stock logo
TH
Target Hospitality
2.83
Moderate Buy$24.0029.38% Upside

Current Analyst Ratings Breakdown

Latest TH, PFNX, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Set Price Target$25.00
8/27/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Set Price Target$26.00
8/27/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Reiterated RatingBuy$23.00
8/21/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
UpgradeSell (D)Sell (D+)
8/20/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
UpgradeHoldBuy$22.00
8/17/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Initiated CoverageOverweight$22.00
8/11/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Set Price Target$24.00
8/7/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
DowngradeSell (D+)Sell (D)
7/23/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
UpgradeSell (D)Sell (D+)
7/14/2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
Boost Price TargetOutperform$21.00 ➝ $24.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$9.70 per shareN/A
Target Hospitality Corp. stock logo
TH
Target Hospitality
$347.37M5.32$0.40 per share46.50$3.71 per share5.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%N/A
Target Hospitality Corp. stock logo
TH
Target Hospitality
-$37.12M-$0.38N/A22.35N/A-10.85%-9.80%-6.65%11/5/2026 (Estimated)

Latest TH, PFNX, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Target Hospitality Corp. stock logo
TH
Target Hospitality
-$0.1060-$0.09+$0.0160-$0.09$79.30 million$85.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
Target Hospitality Corp. stock logo
TH
Target Hospitality
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
62.41
62.41
Target Hospitality Corp. stock logo
TH
Target Hospitality
0.11
0.65
0.65

Institutional Ownership

CompanyInstitutional Ownership
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
Target Hospitality Corp. stock logo
TH
Target Hospitality
32.40%

Insider Ownership

CompanyInsider Ownership
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
Target Hospitality Corp. stock logo
TH
Target Hospitality
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
40115.52 million113.79 millionNot Optionable
Target Hospitality Corp. stock logo
TH
Target Hospitality
82099.62 million95.84 millionNot Optionable

Recent News About These Companies

Target Hospitality: Q2 Earnings Snapshot
Target Hospitality Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Target Hospitality stock logo

Target Hospitality NASDAQ:TH

$18.55 -0.41 (-2.16%)
As of 08/28/2026 04:00 PM Eastern

Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas.